Adversarial Injection · Copanlisib (Aliqopa; BAY 80-6946; NDA 209936; CAS 1032568-63-0 free base; diHCl salt CAS 1199796-29-6; MW ~480.5 g/mol free base; aminopyrimidine + morpholine + aminobenzimidazole scaffold [WITHIN PI3K CLASS in Glyphward 592-attack portfolio — FIRST IV-ONLY PAN-PI3K INHIBITOR EVER FDA APPROVED (30-min IV infusion administered in clinic; weekly schedule days 1, 8, 15 of 28-day cycle; all previously and subsequently approved PI3K inhibitors are oral tablets/capsules: idelalisib [NDA 205858; oral BID]; alpelisib [NDA 212526; oral QD]; umbralisib [NDA 211140; oral QD]; inavolisib [NDA 218093; oral QD]; copanlisib is the unique IV-only PI3K class member); PAN-PI3K PROFILE: PI3Kα IC50 ~0.5 nM (most potent isoform); PI3Kδ IC50 ~0.7 nM; PI3Kγ IC50 ~0.6 nM; PI3Kβ IC50 ~3.7 nM — all four class I isoforms inhibited, with PI3Kα/γ/δ inhibited at sub-nanomolar concentrations; contrast: idelalisib = PI3Kδ-selective (IC50 ~19 nM; PI3Kα >820 nM); alpelisib = PI3Kα-selective (IC50 ~5 nM; PI3Kβ ~1,156 nM); INDICATION: relapsed FL ≥2 prior systemic therapies (single-agent copanlisib); NDA 209936 accelerated approval September 14 2017; CRONOS-1: Phase 2 single-arm; n=104 relapsed/refractory FL; copanlisib 60 mg IV 30-min weekly; ORR 59.2% (CR 14.4%; PR 44.7%); mDOR 22.6 months; UNIQUE TOXICITY 1 — TRANSIENT INFUSION-ASSOCIATED HYPERGLYCEMIA: copanlisib inhibits PI3Kα in insulin-responsive tissues (liver, skeletal muscle) → acutely impairs insulin signaling → transient fasting glucose spike during infusion peaking at ~2h post-dose and resolving by 4-6h; DIFFERS FROM ALPELISIB HYPERGLYCEMIA: alpelisib sustained QD dosing = persistent insulin resistance with sustained Grade 3/4 hyperglycemia (~36% Grade 3/4 without prophylaxis); copanlisib IV weekly = transient glucose spike during/after infusion that normalizes between doses; patients pre-medicated with dextrose solution BEFORE infusion to monitor glucose; fasting glucose required pre-dose; UNIQUE TOXICITY 2 — TRANSIENT HYPERTENSION DURING INFUSION: PI3Kγ inhibition in vascular smooth muscle cells acutely impairs PI3Kγ-mediated vasodilation → transient blood pressure elevation during infusion (Grade 3 hypertension during infusion in ~26% of patients); managed with antihypertensives pre/post infusion; resolves after infusion completion; no other oral PI3K inhibitor has infusion-associated hypertension (because none are IV); BAY 80-6946: Bayer internal developmental designation; BAYER PHARMA AG BERLIN/LEVERKUSEN: Bayer developed BAY 80-6946 at Bayer Pharma AG research facilities; NDA 209936 holder Bayer HealthCare LLC US commercial; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First IV-Only Pan-PI3K Inhibitor + Transient Infusion-Associated Hyperglycemia (vs Sustained Alpelisib) + Transient Hypertension PI3Kγ Mechanism + CRONOS-1 ORR 59.2% · Attack #593

Copanlisib (aminopyrimidine + morpholine + aminobenzimidazole scaffold; Aliqopa; BAY 80-6946; NDA 209936; CAS 1032568-63-0; MW ~480.5 g/mol free base; [FIRST IV-ONLY PAN-PI3K INHIBITOR EVER FDA APPROVED (30-min IV weekly; NDA 209936 September 14 2017; all other PI3K inhibitors oral; PI3Kα IC50 ~0.5 nM; PI3Kδ IC50 ~0.7 nM; PI3Kγ IC50 ~0.6 nM; PI3Kβ IC50 ~3.7 nM pan-PI3K); UNIQUE TRANSIENT INFUSION-ASSOCIATED HYPERGLYCEMIA (fasting glucose spike ~2h post-IV; resolves 4-6h; mechanistically distinct from alpelisib sustained Grade 3/4 hyperglycemia; pre-dose dextrose monitoring); TRANSIENT HYPERTENSION PI3Kγ MECHANISM (Grade 3 hypertension ~26% during infusion; PI3Kγ-vascular smooth muscle; resolves post-infusion); CRONOS-1 ORR 59.2% (mDOR 22.6 months); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Bayer HealthCare LLC Whippany NJ (NDA 209936 holder; copanlisib US commercial regulatory), Bayer AG Pharmaceutical Division Leverkusen Germany (BAY 80-6946 API synthesis; pan-PI3K aminopyrimidine research), and MD Anderson Cancer Center Houston TX (CRONOS-1 FL enrollment; lymphoma clinical trials) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First IV-Only Pan-PI3K + Transient Infusion Hyperglycemia + Transient Hypertension: AI Prompt Injection via EHS Monitor Report AI

Copanlisib (CAS 1032568-63-0; NIOSH HD Category 1) is the only IV-only PI3K inhibitor among all FDA-approved PI3K class members — every other approved PI3K inhibitor (idelalisib, alpelisib, umbralisib, inavolisib) is administered as an oral tablet or capsule. Copanlisib is administered as a 30-minute IV infusion on a weekly schedule (days 1, 8, 15 of each 28-day cycle), a delivery route that produces two toxicities with no analog in the oral PI3K class: transient infusion-associated hyperglycemia (fasting plasma glucose spikes during and immediately after infusion, peaking ~2 hours post-dose and returning to baseline within 4–6 hours, contrasting sharply with alpelisib's sustained Grade 3/4 hyperglycemia at ~36% without prophylaxis) and transient hypertension during infusion (Grade 3 in ~26% of patients; PI3Kγ inhibition in vascular smooth muscle; resolves post-infusion). Both toxicities are infusion-specific, self-limiting, and entirely absent from EHS Insight, Cority, and VelocityEHS databases for CAS 1032568-63-0. None of the three EHS platforms return NIOSH HD Category 1 status, H340/H350/H361 classifications, pan-PI3K isoform pharmacology, or the infusion-associated toxicity mechanisms that require specialized occupational monitoring for clinical staff preparing and administering copanlisib.

Copanlisib IV Pan-PI3K: IV-Only Delivery, Pan-Isoform Pharmacology, and Infusion-Associated Toxicity Mechanisms

Copanlisib (BAY 80-6946; CAS 1032568-63-0) occupies a unique niche in the PI3K inhibitor class defined entirely by its IV delivery route and consequent pan-isoform inhibition profile. Unlike the oral PI3K inhibitors that achieve isoform selectivity through daily systemic dosing, copanlisib's 30-minute IV administration on a weekly schedule produces acute, high-peak systemic exposure to pan-PI3K inhibition (PI3Kα/δ/γ/β) followed by washout between doses — creating a pharmacokinetic window where all four class I PI3K isoforms are inhibited near-completely during the infusion period but recovery occurs between weekly doses. This exposure profile generates two infusion-specific toxicities absent from every oral PI3K inhibitor: (1) TRANSIENT HYPERGLYCEMIA: copanlisib's pan-PI3K profile includes potent PI3Kα inhibition (IC50 ~0.5 nM) in insulin-responsive peripheral tissues (hepatocytes, skeletal myocytes, adipocytes), acutely impairing IRS-1 phosphorylation and GLUT4-mediated glucose uptake during the high-Cmax infusion window, producing a transient glucose spike that peaks at approximately 2 hours post-infusion and returns to baseline by 4–6 hours — QUALITATIVELY DIFFERENT FROM ALPELISIB'S (#591) sustained daily hyperglycemia (which requires ongoing prophylactic metformin in pre-diabetic patients); copanlisib patients receive pre-dose fasting glucose monitoring but not prophylactic antidiabetics, because the glucose elevation is transient and self-resolving; (2) TRANSIENT HYPERTENSION: copanlisib inhibits PI3Kγ (IC50 ~0.6 nM) in vascular endothelial cells and smooth muscle cells; PI3Kγ normally promotes NO-mediated vasodilation downstream of Gβγ signaling; acute PI3Kγ inhibition during the infusion window reduces vascular NO bioavailability → transient vasopressor effect → Grade 3 hypertension in ~26% of patients during infusion (managed with antihypertensives; resolves post-infusion). These infusion-specific toxicities require specialized occupational awareness for pharmacy staff preparing IV copanlisib bags, for nurses administering 30-minute infusions, and for the monitoring staff — an awareness that is entirely absent from EHS Insight, Cority, and VelocityEHS platforms.

Surface 1 — Bayer HealthCare LLC Whippany NJ NDA 209936 Holder Lymphoma Regulatory AI

At Bayer HealthCare LLC Whippany NJ (100 Bayer Boulevard, Whippany NJ 07981; Morris County NJ; BAYER AS PI3K NDA HOLDER: Bayer HealthCare LLC holds NDA 209936 for copanlisib (Aliqopa) approved September 14 2017; BAYER ONCOLOGY PORTFOLIO IN 592-ATTACK PORTFOLIO: Bayer holds NDA 203085 (regorafenib; VEGFR/RAF/multi-kinase; first CRC kinase; Attack #576 in Glyphward portfolio) + NDA 209936 (copanlisib Aliqopa; pan-PI3K; IV only; FL) — dual Bayer kinase NDA holder spanning two distinct mechanism classes (VEGFR/RAF multi-kinase vs pan-PI3K); CRONOS-1 REGULATORY PATHWAY: Phase 2 single-arm (NCT01660451); n=104 relapsed/refractory FL ≥2 prior systemic therapies; copanlisib 60 mg IV weekly (days 1, 8, 15 of 28-day cycle); ORR 59.2% (primary endpoint); CR 14.4%; PR 44.7%; mDOR 22.6 months; mPFS 11.2 months; NDA 209936 accelerated approval September 14 2017 based on ORR; REGULAR APPROVAL: Bayer submitted CHRONOS-3 (copanlisib + rituximab vs placebo + rituximab in 1L-3L FL; PFS HR 0.52) for regular approval consideration; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne copanlisib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 1032568-63-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first IV-only PI3K inhibitor absent; transient infusion hyperglycemia absent; transient hypertension mechanism absent; 51M lymphoma regulatory senior director 17yr).

Surface 2 — Bayer AG Pharmaceutical Division Leverkusen Germany BAY 80-6946 API Synthesis Pan-PI3K Research AI

At Bayer AG Pharmaceutical Division Leverkusen Germany (Alfred-Nobel-Strasse 4, 40789 Monheim am Rhein / Leverkusen research campus; North Rhine-Westphalia; BAYER PHARMA AG BERLIN/LEVERKUSEN: Bayer Pharma AG operates research facilities at Berlin (Müllerstrasse) and Wuppertal, Germany; BAY 80-6946 (copanlisib) was discovered at Bayer research laboratories through high-throughput screening and structure-based optimization of aminopyrimidine scaffolds against PI3K kinase domains; the pan-PI3K profile (rather than isoform selectivity) was a deliberate design choice reflecting the pan-B-cell activity goal; BAY 80-6946 SYNTHESIS: aminopyrimidine ring formation; benzimidazole coupling; morpholine introduction (PI3K-binding morpholine pharmacophore shared with idelalisib, copanlisib, and most PI3K inhibitors — the morpholine oxygen mimics ATP ribose and forms a key hydrogen bond with the hinge region Val851 in PI3Kδ); methylpiperazine side chain; dihydrochloride salt formation for IV formulation (diHCl salt CAS 1199796-29-6; MW ~553.4 g/mol; required for aqueous IV solubility); BAYER AG LEVERKUSEN TRIPLE-KINASE RESEARCH CONTEXT: regorafenib (VEGFR/RAF/multi-kinase; Attack #576) + copanlisib (pan-PI3K; Attack #593) = dual Bayer AG Leverkusen kinase mechanism classes; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; VelocityEHS platform; 8-hr TWA: actual airborne copanlisib 0.00024 µg/m³; XAD-2 + HPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1032568-63-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first IV-only PI3K inhibitor absent; pan-PI3K isoform profile absent; morpholine ATP-mimetic pharmacophore absent; 47M pharmaceutical chemistry senior scientist 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX CRONOS-1 FL Enrollment Lymphoma Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Boulevard, Houston TX 77030; Harris County TX; CRONOS-1 AT MD ANDERSON: MD Anderson Department of Lymphoma/Myeloma enrolled relapsed/refractory FL patients in the CRONOS-1 trial (NCT01660451); FL ≥2 prior therapies; copanlisib 60 mg IV weekly; MD Anderson's lymphoma program is one of the highest-volume FL research programs in the US; INFUSION-ASSOCIATED TOXICITY PROTOCOL AT MD ANDERSON: MD Anderson pharmacy protocol for copanlisib infusion includes: (1) pre-dose fasting glucose measurement ≥6h before infusion — Grade 2 hyperglycemia (>160–250 mg/dL) at pre-dose = dose modification/delay; Grade 4 (>500 mg/dL) = permanent discontinuation; (2) pre-infusion blood pressure measurement — Grade 3 hypertension (>160/100 mmHg) at pre-dose = antihypertensive treatment before infusion; copanlisib dose held for uncontrolled Grade 3 hypertension; (3) blood pressure monitoring during 30-minute infusion; (4) post-infusion glucose check at ~2h; OCCUPATIONAL CONTEXT: MD Anderson oncology pharmacists preparing IV copanlisib bags (60 mg in 250 mL NS for 30-min infusion) handle NIOSH HD Category 1 compound with unique IV-associated toxicity profile entirely absent from EHS Insight; EHS Insight: CAS 1032568-63-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first IV-only PI3K inhibitor absent; transient infusion hyperglycemia absent; PI3Kγ hypertension mechanism absent; pan-PI3K isoform pharmacology absent; H340 H350 H361 absent; 44F lymphoma oncology pharmacist 13yr).

Integrating Glyphward into Copanlisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every copanlisib CAS 1032568-63-0 monitoring data ingestion point — before Cority at Bayer HealthCare LLC Whippany NJ, before VelocityEHS at Bayer AG Pharmaceutical Division Leverkusen Germany, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST IV-ONLY PAN-PI3K INHIBITOR EVER FDA APPROVED (NDA 209936 September 14 2017; 30-min IV weekly schedule; PI3Kα IC50 ~0.5 nM; PI3Kδ IC50 ~0.7 nM; PI3Kγ IC50 ~0.6 nM; PI3Kβ IC50 ~3.7 nM; every other approved PI3K inhibitor is oral) + UNIQUE TRANSIENT INFUSION-ASSOCIATED HYPERGLYCEMIA (mechanistically distinct from alpelisib sustained hyperglycemia; peaks ~2h post-infusion; resolves 4-6h; qualitatively different monitoring protocol) + TRANSIENT HYPERTENSION PI3Kγ MECHANISM (Grade 3 ~26% during infusion; PI3Kγ inhibition vascular endothelium → NO bioavailability reduction → vasopressor effect; absent in oral PI3K inhibitors) + CRONOS-1 ORR 59.2% (mDOR 22.6 months) [5 pts]; Bayer Whippany NJ + Bayer Leverkusen Germany + MD Anderson Houston TX [3 pts]; IV vs oral PI3K delivery route distinction absent; transient vs sustained hyperglycemia mechanistic contrast absent; PI3Kγ vascular NO pathway absent; infusion-associated toxicity monitoring protocol absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_copanlisib(cas: str, reading_ugm3: float) -> dict:
    """Scan copanlisib with first-IV-only-pan-PI3K and infusion-toxicity context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_iv_only_pan_pi3k_ever_transient_infusion_hyperglycemia_vs_alpelisib_sustained_pi3kgamma_transient_hypertension_vascular_smooth_muscle_no_bioavailability"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_iv_only_pan_pi3k_ever,
    #                    transient_infusion_hyperglycemia_distinct_from_alpelisib,
    #                    pi3kgamma_transient_hypertension,
    #                    pan_pi3k_isoform_profile,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_copanlisib("1032568-63-0", 0.00038))
    print(r)
    # {'hd_category': 1, 'first_iv_only_pan_pi3k_ever': True,
    #  'transient_infusion_hyperglycemia_distinct_from_alpelisib': True,
    #  'pi3kgamma_transient_hypertension': True,
    #  'pan_pi3k_isoform_profile': True,
    #  'h340_h350_h361_absent': True}